Results 261 to 270 of about 115,987 (377)

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton   +9 more
wiley   +1 more source

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes [PDF]

open access: yes, 2016
Daisuke Koya, Keizo Kanasaki, Sen Shi
core   +1 more source

Ethnic differences in the comparative effectiveness of second‐line type 2 diabetes medications in preventing cardiovascular disease

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1013-1023, February 2026.
Abstract Aim To investigate ethnic differences in the comparative effectiveness of sulfonylureas (SU), dipeptidyl peptidase‐4 inhibitors (DPP4i) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) on cardiovascular outcomes. Materials and Methods We identified adults with type 2 diabetes in UK electronic health records initiating SU, DPP4i or SGLT2i
Mia Harley   +7 more
wiley   +1 more source

Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1499-1507, February 2026.
Abstract Aims Published literature has raised concerns regarding a causal association between glucagon‐like peptide 1 receptor agonist (GLP‐1RA) use and thyroid cancer risk in adults. In this analysis, we evaluated the association between thyroid cancer risk and GLP‐1RA use.
Tina Vilsbøll   +8 more
wiley   +1 more source

Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1191-1200, February 2026.
Abstract Aim This study aimed to investigate the efficacy and safety of bi‐weekly cofrogliptin treatment as a replacement for daily dipeptidyl peptidase‐4 inhibitors (DPP‐4is) in Chinese patients with type 2 diabetes mellitus (T2DM). Methods This multicenter, open‐label, randomized controlled study assigned participants in a 1:1 ratio to either the ...
Congqing Pan   +10 more
wiley   +1 more source

Exploring the roles of airway dipeptidyl peptidase 1 in obstructive airway disease. [PDF]

open access: yesERJ Open Res
Tanabe N   +14 more
europepmc   +1 more source

Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization

open access: green, 2013
Shaogao Zeng   +10 more
openalex   +1 more source

Home - About - Disclaimer - Privacy